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Scope: The dietary fatty acid cis9,trans11 conjugated linoleic acid (cis9,trans11 CLA) has been
shown to modify the function of endothelial cells, monocytes, and platelets, all of which are
involved in the development of atherosclerosis. Potential mechanisms for the platelet effects
have not been assessed previously. In this study, we assessed how supplementation of the diet
with an 80:20 cis9,trans11 CLA blend affects the platelet proteome.
Methods and results: In a double-blind, randomized, placebo-controlled, parallel-group trial, 40
overweight but apparently healthy adults received either 4 g per day of cis9,trans11 CLA-enriched
oil or placebo oil, consisting of palm oil and soybean oil, for 3 months. Total platelet proteins
were extracted from washed platelets, separated using two-dimensional gel electrophoresis and
differentially regulated protein spots were identified by LC-ESI-MS/MS. Supplementation with
the CLA blend, compared with placebo, resulted in significant alterations in levels of 46 spots
(p < 0.05), of which 40 were identified. Network analysis revealed that the majority of these
proteins participate in regulation of the cytoskeleton and platelet structure, as well as receptor
action, signaling, and focal adhesion.
Conclusion: The platelet proteomics approach revealed novel insights into regulation of cellular
biomarkers of atherogenic and thrombotic pathways by an 80:20 cis9,trans11 CLA blend.
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1 Introduction
Consumption of dietary conjugated linoleic acids (CLAs),
which belong to the group of trans fatty acids and are present
Correspondence: Dr. Baukje de Roos, Rowett Institute of Nutrition
& Health, University of Aberdeen, Greenburn Road, Bucksburn,
Aberdeen AB21 9SB, United Kingdom
E-mail: b.deroos@abdn.ac.uk
Fax: +44-1224-438629
Abbreviations: CDC42hs, cell division control protein 42 ho-
molog; cFXIII, cellular coagulation factor XIII; CLA, conjugated
linoleic acid; KEGG, Kyoto Encyclopedia of Genes and Genomes;
PRP, platelet rich plasma
in ruminant products including milk, cheese, and beef
[1], may beneficially influence inflammation [2], eicosanoid
metabolism in both platelets and endothelium [3], and lipid
metabolism [4]. In addition, these fatty acids inhibit the de-
velopment of atherosclerosis, at least in animal models [4–9].
The effect in animal models is thought to be isomer-specific,
with cis9,trans11 CLA being the active isomer inhibiting
atherogenesis [10–14].
Atherosclerosis is a multifactorial inflammatory arterial
disease involving various cell types including endothelial
cells, monocytes, and platelets [15]. Indeed, activated blood
platelets contribute to the early stages of plaque formation
within blood vessels, as well as to thrombus formation [16].
Therefore, platelets can be considered as a useful model to
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assess the effects of cis9,trans11 CLA on mechanisms in-
volved in atherogenesis. A few studies have indicated that the
cis9,trans11 CLA isomer in particular may prevent platelet
activation and aggregation in vitro, and may display anti-
coagulant properties [3, 17–20]. The effects of cis9,trans11
CLA on platelet function could be mediated through mul-
tiple mechanisms. Blood platelets appear an ideal cell type
to apply proteomics and study the atheropreventive poten-
tial of cis9,trans11 CLA. First, because they play a pivotal
role in cardiovascular disease (CVD) progress and second,
since they synthesize proteins and modify the proteins post-
translationally [21]. Therefore, we investigated the effects of
supplementing the diet with cis9,trans11 CLA on regulation
of the platelet proteome in humans, by visualizing the biolog-
ical functions of the regulated proteins as a network [22]. This
platelet proteomics approach could extend the availability of
relevant biomarkers to properly assess the physiological and
biochemical effects of cis9,trans11 CLA in humans.
2 Materials and methods
2.1 Subjects and intervention
The study was carried out in accordance with the ethical prin-
ciples of the Declaration of Helsinki. The study protocol was
approved by the Institutional Review Board of the University
Medical Center Utrecht in Utrecht, The Netherlands. All par-
ticipants provided written informed consent. This trial was
registered at www.clinicaltrials.gov as NCT00706745. The
first 40 overweight but apparently healthy subjects that were
recruited for participating in a larger trial investigating the
effects of cis9,trans11 CLA supplementation for 6 months on
aortic stiffness [23], who were eligible based on the additional
selection criteria for this study, and who were willing to do-
nate an additional blood sample for platelet proteomic ana-
lysis, were invited to participate. In these volunteers, blood
samples were obtained at baseline and after 3 months of in-
tervention. Details on recruiting and randomization in the
core study are described elsewhere [23]. Inclusion criteria at
screening for this study were apparently healthy men and
women, aged 40–70 years, with a body mass index (BMI; in
kg/m2) of ≥25. The main exclusion criteria at screening were:
a systolic blood pressure of ≥160 mm Hg or a diastolic of
≥90 mm Hg, or current use of blood pressure lowering drugs;
a total cholesterol concentration of ≥8 mmol/L or current
use of lipid lowering drugs; inability to perform pulse wave
velocity measurements; clinical signs of renal, hepatic, or
hematological diseases; currently taking any medication or
dietary supplements known to alter platelet function or the
hemostatic system; undertaking ≥6 h of vigorous exercise
per week; having donated blood within a month of blood sam-
pling; taking contraceptives or hormone replacement therapy
or having an abnormal menstrual cycle.
Eligible participants were randomly assigned in the core
study to receive either the 80:20 cis9,trans11 CLA blend or
placebo supplements. The intervention and placebo oil sup-
plements were given as four soft gel capsules of 1 g oil each
daily. This supplied about 1.5 energy% based on a daily energy
intake of 10 MJ. The CLA capsules provided 3.1 g CLA isomers
or 1.1 energy%, of which 80% was in the form of cis9,trans11
CLA and 20% in the form of trans10,cis12 CLA. The placebo
capsules consisted of a blend of palm oil and soybean oil,
which resembles the average fatty acid composition of the fat
consumed by a Western population. Both supplements in-
cluded 0.05% (v/v) TocoblendTM L50 IP (IOI Loders Croklaan,
Wormerweer, NL) containing a mixture of  (5–9%),  (1–
2%),  (25–33%), and  (10–15%) tocopherols in sunflower
oil. Capsules were produced and supplied by Lipid Nutri-
tion, Wormerveer, The Netherlands. Fatty acid composition
of both types of capsules has been described previously [23].
2.2 Blood sampling and platelet isolation
The volunteers were asked to provide a fasted blood sample
(55 mL) at baseline and after 3 months of intervention. The
time frame of 3 months has been chosen as the incorporation
of dietary fatty acids is known to happen as fast as 6 days after
the onset of intervention and the lifespan of a platelet is only
10 days [24]. Therefore, any change in platelet function as a
result of either incorporation of dietary fatty acids into the
membrane of platelets or the direct action of the fatty acids
on inflammatory or thrombogenic pathways should be appar-
ent after 20 days. As we were interested in long-term estab-
lished effects of the 80:20 cis9,trans11 CLA blend, a period of
3 months would be sufficient to detect any effects on levels
of platelet proteins.
Blood sampling for platelet isolation in monovettes with
trisodium citrate as anticoagulant was performed as described
previously [25] and the first 5 mL of blood was discarded.
We obtained platelets for protein isolation from platelet rich
plasma (PRP), which was prepared within 30 min by cen-
trifuging samples at 100 × g for 17 min at room temperature.
The platelets contained in the upper two-thirds of PRP were
carefully collected and precipitated by a second centrifuga-
tion step at 900 × g for 12 min at room temperature. PGI2
(50 ng/mL final concentration) was added in all washing steps
to minimize platelet activation during preparation of platelet
pellet. The platelet pellet was resuspended in cold Tyrodes
buffer (140 mM NaCl, 3 mM KCl, 12 mM NaHCO3, 0.4 mM
NaH2PO4, 2 mM MgCl2, 0.1% (w/v) glucose, adjusted to pH
7.33 with HEPES), centrifuged at 900 × g for 12 min at 4C
and stored at −80C until further analysis. The platelet pellet
typically contained less than 1% white blood cells and ∼7%
red blood cells, as assessed by a differential full blood count
analyzer (model KX-21N, Sysmex, Milton Keynes, UK).
2.3 Protein extraction and proteome analysis
Total platelet proteins were extracted according to a protocol
described by us previously [25] with modifications. The
pellets were homogenized with a sonicator for two times 10
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s on ice in 100 L extraction buffer containing 7 M urea, 2
M thiourea, 2% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), and 0.06% proteinase inhibitor
cocktail (Roche, Burgess Hill, UK) and the homogenates
were centrifuged at 1100 × g for 10 min at 4C. Protein
concentrations in the supernatant were measured with a
RC DC protein assay (Bio-Rad, Hemel Hempstead, UK)
applying a reducing agent compatible (RC) and detergent
compatible (DC) modification of Lowry’s method. Samples
for two-dimensional (2D) gel electrophoresis were run in
batches of 12 that were randomized for intervention group
and subject to prevent running order bias for proteome anal-
ysis, as described by us previously [10,26] with modifications.
Briefly, immobilizing pH gradient (IPG) strips (17 cm, pI
4–7, Bio-Rad) were rehydrated passively in 340 L extraction
buffer containing 15 L freshly prepared 30% (w/v) DTT and
250 g protein per sample for 1 h at 20C followed by active
rehydration for 16 h under low voltage (50 V per strip). To
separate proteins in the first dimension the recommenda-
tions of Bio-Rad were followed. SDS-PAGE was performed
on 18 × 18 cm acrylamide gradient (8–16%) gels for the
separation of proteins in the second dimension. Flamingo
(Bio-Rad) fluorescent stained gels were scanned using a Bio-
Rad FX scanner, set at medium intensity with a resolution
of 100 m, and analyzed using the automatic matching tool
within PDQuest software (Bio-Rad). Spots were excised from
the gel using a robotic spot cutter (Bio-Rad), trypsinized
using a MassPrep Station (Micromass, Manchester, UK).
Liquid chromatography-electrospray ionization/multistage
mass spectrometry (LC-ESI-MS/MS) was performed using
a Q-Trap triple quadrupole mass spectrometer fitted with
a nanospray ion source (Applied Biosystems/MDS Sciex,
Framingham, USA). The total ion current (TIC) data were
submitted for database searching using the MASCOT search
engine (Matrix Science Ltd., London, UK) using the MSDB
database (version 20060831) with the following search
criteria: allowance of 0 or 1 missed cleavages; peptide mass
tolerance of ± 1 Da; fragment mass tolerance of ± 0.8 Da,
trypsin as digestion enzyme; carbamidomethyl modification
of cysteine; methionine oxidation as partial modification; and
charged state as MH+. Proteins were considered identified
when at least two matched peptides with individual ion scores
> 41 were found, indicating identity or extensive homology
with 95% certainty (Supporting Information Table S1).
2.4 Visualization of pathway annotations with
Cytoscape
To visualize the regulated proteins in the context of their bi-
ological function, a network was generated using pathways
from the Kyoto Encyclopedia of Genes and Genomes (KEGG),
which is generally considered one of the most complete sets
of biological pathways available [27]. The network is a bipar-
tite graph containing a set of nodes representing regulated
proteins and a set of nodes representing pathways. An edge is
added between a protein and pathway node when the protein
plays a role in that pathway. To map the measured proteins
with the protein and gene identifiers in the pathways, both
were translated to UniProt identifiers using the BridgeDb
library [28]. The constructed network was visualized using
Cytoscape (version 2.8.2) [22]. Protein nodes were colored ac-
cording to their differential up- or down-regulation. In a few
cases where more than one protein isoform was identified
per UniProt identifier, the protein node was segmented and
each segment was colored according to the regulation of the
corresponding isoform. Cytoscape plots were used to identify
potential regulatory protein hubs (defined as a protein that
plays a role in high number of different pathways) regulated
by supplementation with the 80:20 cis9,trans11 CLA blend.
2.5 Statistical analysis
Data are presented as mean ± standard deviation (SD). Nor-
malized data, as calculated by the PDQuest software (Bio-Rad)
were used. Data were log-transformed and the changes in in-
tensities for each spot between baseline and 3 months for
CLA supplementation and for placebo were compared using
an unpaired t-test and assuming equal variances. Tests were
calculated in R (R foundation for Statistical Computing, Vi-
enna, Austria). Spots significant at p < 0.05 were selected for
identification. False discovery rates were calculated using the
method described by [29]. The q-values ranged from about
0.01 for the most significant proteins to 0.31 at a p-value of
0.05. This indicates that while some nonregulated proteins
will inevitably have been included, more than two-thirds are
likely to be true positive results from the statistical testing.
3 Results
The baseline characteristics of the 40 participants in this study
were similar between both intervention groups (Table 1).
2D gel electrophoresis revealed in total 584 protein spots
from the protein extract of washed platelets. Intervention with




Age (year) 60.0 ± 4.1 58.9 ± 3.9
Gender (male/female) 12/8 10/10
Current smoking (n (%)) 2 (10%) 2 (10%)
BMI (kg/m2) 27.9 ± 2.9 28.7 ± 3.0
Mean systolic blood
pressure (mm Hg)
126.7 ± 12.3 124.5 ± 10.0
Mean diastolic blood
pressure (mm Hg)
75.3 ± 9.2 75.5 ± 6.1
Values represent mean ± SD for age, BMI, and blood pressure
outcomes.
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an 80:20 cis9,trans11 CLA blend for 3 months compared with
placebo oil was associated with significant changes (p < 0.05)
in 74 protein spots, of which 46 single valid protein spots
were cut for identification. Of these, 40 protein spots were
identified using LC-ESI-MS/MS resulting in 31 different pro-
teins, some with more than one changed spot. The proteins
were classified in categories according to their currently rec-
ognized major function based on the protein knowledge base
UniProtKB [30] (Table 2). Additional data on the LC-ESI-
MS/MS identification of proteins are available in Supporting
Information Table S1. CLA-regulated platelet proteins were
mainly those involved in platelet structure, receptor action,
and cell signaling.
In order to assess the impact of changes in protein levels
on the regulation of major pathways in platelets, we explored
the results on protein levels with Cytoscape. Cytoscape [22] is
an open source software platform to visualize complex net-
works in general, which has already been successfully utilized
for the network analysis of MicroArray datasets to elucidate
mechanisms in CVD [31]. We used this tool in a novel ap-
proach to visualize a network of regulated proteins assessed
by 2D gel electrophoresis and their pathway annotations.
Twenty two out of the 31 regulated and identified proteins
were part of 52 different pathways annotated in KEGG, and
these pathways were connected by 93 edges (Fig. 1). This net-
work revealed that the majority of regulated proteins was in-
volved in pathways that are very relevant for platelet function,
such as focal adhesion, regulation of the actin cytoskeleton,
aggregation, and the coagulation cascade. The central regula-
tory protein hubs affected by the 80:20 cis9,trans11 CLA blend
were GTP-binding protein CDC42hs, integrin alpha-IIb pre-
cursor, and two cytoskeletal proteins, i.e., alpha-actinin-1 and
a hypothetical protein of the actin family. GTP-binding pro-
tein CDC42hs (UniProt accession number P60953, change in
spot intensity −2.011, p = 0.007) with the corresponding gene
was involved in 22 biochemical pathways. Integrin alpha-IIb
precursor (UniProt accession number P08514, change in spot
intensity −1.184, p = 0.036) with the corresponding gene
was involved in nine biochemical pathways. Alpha-actinin-1
(UniProt accession number P12814, change in spot intensity
2.348, p = 0.047) with the corresponding gene was involved
in eight biochemical pathways and the hypothetical protein
of the actin family (UniProt accession number Q8WVW5,
change in spot intensity 2.610, p = 0.030) with the correspond-
ing gene, annotated as actin, was involved in 16 biochemical
pathways.
4 Discussion
Platelets in their roles in hemostasis, atherogenesis, and
thrombosis undergo shape change, adhesion, secretion of
chemokines and coagulation components, fibrinogen bind-
ing to receptors, and thromboxane A2 formation leading to
aggregation. Although platelets are enucleate they are yet ca-
pable of translation of selected proteins and post-translational
modification of a large number of proteins, as well as up-
take and storage of plasma components. Therefore, blood
platelets appear an ideal cell type for the application of pro-
teomics [21] in order to study the beneficial potential of the
80:20 cis9,trans11 CLA blend on platelets function and CVD
progression.
Nutritional supplementation of healthy overweight and
obese subjects with the 80:20 cis9,trans11 CLA blend for 3
months significantly altered the regulation of platelet pro-
teins in unstimulated platelets when compared with those
taking placebo oil. Albeit that our investigational product
consisted mainly of cis9,trans11 CLA, we cannot exclude the
possibility that our results may be partly attributable to the
small content of the trans10,cis12 CLA content of the pro-
duct. CLA-regulated platelet proteins were mainly those in-
volved in platelet structure, receptor action, and cell signal-
ing. This may be important as the protein distribution in
resting platelets can influence the response after platelet sti-
mulation. Data from in vitro studies and human intervention
trials assessing the effect of CLA on platelet aggregation are
very limited. Incubation with the CLA isomers cis9,trans11
and trans10,cis12 CLA, or a mix of both CLA isomers, re-
duced arachidonic acid-induced platelet aggregation as well
as thromboxane B2 production ex vivo, and the isomeric mix
was also effective in inhibiting collagen-induced platelet ag-
gregation compared with linoleic acid [17]. In one study in
healthy women, no effect on agonist-induced platelet aggre-
gation or other blood clotting parameters was observed upon
supplementation with 3.9 g/day CLA (n = 10), compared with
sunflower oil (n = 7) [19], but this study may have lacked statis-
tical power to reveal any relevant antiplatelet effects. However,
in patients with type 2 diabetes, supplementation with 13.0
g/day of 50:50 CLA mix (n = 16), compared with placebo oil (n
= 16), significantly decreased fibrinogen levels [32]. In post-
menopausal women, fibrinogen and plasminogen activator
inhibitor-1 levels were significantly reduced upon interven-
tion with CLA milk (4.7 g/day cis9,trans11 CLA and 0.4 g/day
trans10,cis12 CLA; n = 25), compared with 50:50 CLA mix
(2.3 g/day cis9,trans11 CLA and 2.2 g/day trans10,cis12 CLA;
n = 25), or olive oil [33]. Furthermore, a human trial with
naturally cis9,trans11 CLA-rich pecorino cheese showed a re-
duction in platelet aggregation induced with arachidonic acid
[20]. Both in vitro as well as in vivo studies have reported
that upon exposure, CLA is actually incorporated into the
membranes of platelets and other blood cells [17–19, 34, 35].
Unfortunately, the setting of the human intervention did
not allow us to measure the effect of the 80:20 cis9,trans11
CLA blend on measures of in vivo platelet function. But by
and large, existing evidence indicates that CLA, and espe-
cially the cis9,trans11 CLA isomer, may modify platelet acti-
vation and aggregation, and display anticoagulant proper-
ties. However, mechanisms for these potentially antithrom-
botic or antiatherosclerotic effects have not been studied in
detail.
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Table 2. Differentially regulated proteins after 3 months supplementation with an 80:20 cis9,trans11 conjugated linoleic acid blend identified
by LC-ESI-MS/MS
Accession Protein Kegg pathway SSPa) Mr exp Mr theor Change p-value




Hypertrophic cardiomyopathy [hsa05410]; (3) 405 33.3 32.8 −2.880 0.009
Dilated cardiomyopathy [hsa05414]; (3) 1304 29.8 32.8 −0.128 0.026
Cardiac muscle contraction [hsa04260]; (2)
P19105 Myosin regulatory
light chain 12A
Focal adhesion [hsa04510]; (7) 108 17.9 19.7 −2.323 0.003
Regulation of actin cytoskeleton [hsa04810]; (7) 105 18.0 19.7 −2.004 0.026






Regulation of actin cytoskeleton [hsa04810]; (7) 6102 16.3 227.5 −1.788 0.001
Tight junction [hsa04530]; (5)




Regulation of actin cytoskeleton [hsa04810]; (7) 5508 47.6 65.8 −3.229 0.006
Tight junction [hsa04530]; (5) 6501 47.5 65.8 2.018 0.046
Viral myocarditis [hsa05416]; (2)
P21333 Filamin-A Focal adhesion [hsa04510]; (7) 6514 42.1 280.7 −3.673 0.001




Focal adhesion [hsa04510]; (7) 3503 45.0 40.5 2.610 0.030
Regulation of actin cytoskeleton [hsa04810]; (7)
Tight junction [hsa04530]; (5)
Leukocyte transendothelial migration
[hsa04670]; (4)
Hypertrophic cardiomyopathy [hsa05410]; (3)
Dilated cardiomyopathy [hsa05414]; (3)
Adherens junction [hsa04520]; (3)
Arrhythmogenic right ventricular
cardiomyopathy [hsa05412]; (3)
Viral myocarditis [hsa05416]; (2)




Bacterial invasion of epithelial cells
[hsa05100]; (2)
Vibrio cholerae infection [hsa05110]
P12814 Alpha-actinin-1 Focal adhesion [hsa04510]; (7) 7305 29.1 103.1 2.348 0.047
Regulation of actin cytoskeleton [hsa04810]; (7)
Tight junction [hsa04530]; (5)
Leukocyte transendothelial migration
[hsa04670]; (4)









7405 35.5 76.0 −2.251 0.021
P06396 Gelsolin precursor Regulation of actin cytoskeleton [hsa04810]; (7) 6804 88.1 85.7 −2.474 0.003
Fc gamma R-mediated phagocytosis
[hsa04666]; (2)
7703 79.3 85.7 −3.673 0.000
P37802 Transgelin-2 6101 16.5 22.4 1.508 0.030
Q9Y490 Talin-1 Focal adhesion [hsa04510]; (7) 5704 58.2 269.8 −2.085 0.037
1407 35.1 269.8 −2.320 0.001
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Table 2. Continued.
Accession Protein Kegg pathway SSP Mr exp Mr theor Change p-value
no. name [kDa] [kDa]
(B) Platelet receptor action
P08514 Integrin alpha-IIb
precursor
Focal adhesion [hsa04510]; (7) 3511 41.9 113.4 −1.184 0.036
Regulation of actin cytoskeleton [hsa04810]; (7)
Hypertrophic cardiomyopathy [hsa05410]; (3)
Dilated cardiomyopathy [hsa05414]; (3)
Arrhythmogenic right ventricular
cardiomyopathy [hsa05412]; (3)
Pathways in cancer [hsa05200]; (2)
Hematopoietic cell lineage [hsa04640]
ECM-receptor interaction [hsa04512]
Small cell lung cancer [hsa05222]
P02675 Fibrinogen beta
chain
Complement and coagulation cascades
[hsa04610]; (3)
7608 50.4 55.9 −4.378 0.000
P02679 Fibrinogen gamma
chain
4608 50.0 51.5 −2.460 0.038
Q15084 Protein disulfide
isomerase A6
Protein processing in ER [hsa04141]; (3) 4403 33.9 48.1 2.339 0.010
P00488 Coagulation factor
XIII A chain
Complement and coagulation cascades
[hsa04610]; (3)
7501 44.2 83.3 2.367 0.049
P27797 Calreticulin Protein processing in ER [hsa04141]; (3) 401 39.6 48.1 2.576 0.011
Phagosome [hsa04145]; (2)
Antigen processing and presentation
[hsa04612]; (2)
(C) Cell signalling
Q9ULV4 Coronin 1C 6509 49.1 53.2 1.836 0.046











Focal adhesion [hsa04510]; (7) 3107 16.9 21.7 −2.011 0.007
Regulation of actin cytoskeleton [hsa04810]; (7)
Tight junction [hsa04530]; (5)
Leukocyte transendothelial migration
[hsa04670]; (4)
Neurotrophin signaling pathway [hsa04722]; (3)
Adherens junction [hsa04520]; (3)
Fc gamma R-mediated phagocytosis
[hsa04666]; (2)
Pathogenic Escherichia coli infection
[hsa05130]; (2)
Shigellosis [hsa05131]; (2)
Bacterial invasion of epithelial cells
[hsa05100]; (2)
MAPK signaling pathway [hsa04010]; (2)
Epithelial cell signaling in Helicobacter pylori
infection [hsa05120]
T-cell receptor signaling pathway [hsa04660]
Renal cell carcinoma [hsa05211]




GnRH signaling pathway [hsa04912]
Chemokine signaling pathway [hsa04062]
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Table 2. Continued.
Accession Protein Kegg pathway SSP Mr exp Mr theor Change p-value
no. name [kDa] [kDa]
(D) Chaperone proteins
P11021 78 kDa glucose-
regulated
protein (HSPA5)
Protein processing in ER [hsa04141]; (3) 2703 76.6 72.3 −2.397 0.035
Antigen processing and presentation
[hsa04612]; (2)










Huntington’s disease [hsa05016]; (2) 6201 21.8 21.9 2.499 0.050
Arachidonic acid metabolism [hsa00590]
Amyotrophic lateral sclerosis [hsa05014]
Glutathione metabolism [hsa00480]
P30048 Peroxiredoxin-3 7201 25.3 27.7 3.862 0.000







Glycolysis/gluconeogenesis [hsa00010]; (2) 5316 32.9 39.2 −2.194 0.047
Pyruvate metabolism [hsa00620]; (2)
Butanoate metabolism [hsa00650]
Valine, leucine, and isoleucine biosynthesis
[hsa00290]
Citrate cycle (TCA cycle) [hsa00020]
P14618 Pyruvate kinase
isozymes M1/M2
Glycolysis/gluconeogenesis [hsa00010]; (2) 7406 35.7 57.94 −2.247 0.011
Pyruvate metabolism [hsa00620]; (2)





Huntington’s disease [hsa05016]; (2) 5502 46.6 52.6 −1.537 0.041












4302 30.5 33.3 2.074 0.017




6604 50.7 52.9 −2.243 0.022
(H) Not identified
Not identified 2004 12.2 2.142 0.045
Not identified 3212 21.4 −1.155 0.044
Not identified 4104 14.8 1.848 0.028
Not identified 5001 11.2 1.884 0.031
Not identified 5309 29.2 −1.991 0.020
Not identified 6409 36.3 −1.720 0.010
a) SSP, spot number; Mr exp, experimental molecular weight; Mr theor, theoretical molecular weight; Accession no. from Uniprot Database;
[hsa04810], KEGG pathway entry; (7) total number of proteins regulated by 80:20 cis9,trans11 CLA blend annotated in pathway.
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Figure 1. Cytoscape pathway plot of regulated proteins. Protein regulation is illustrated with a color scheme from blue (decreased) to
yellow (increased). In the case of more than one regulated protein spot per gene identifier, the protein node is segmented in different
colors according to up- or down-regulation. A line (edge) is drawn between a protein and pathway node (in gray) when the protein plays
a role in that pathway. Proteins are labeled with their gene identifiers: ACTG1, hypothetical protein (belongs to actin family); ACTN1,
alpha-actinin-1; ARHGDIA, Rho GDP-dissociation inhibitor 1; CALR, calreticulin; CDC42, GTP-binding protein CDC42hs; F13A1, coagulation
factor XIII A chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; FLNA, filamin-A; GPX1, glutathione peroxidase; GSN,
gelsolin precursor; HSPA5, 78 kDa glucose-regulated protein; ITGA2B, integrin alpha-IIb precursor; MYH9, FLJ00279 protein fragment of
myosin-9; MYL12A, myosin regulatory light chain 12A; PDHB, pyruvate dehydrogenase E1 component subunit beta; PDIA6, protein disulfide
isomerase A6; PKM2, pyruvate kinase isozymes M1/M2; PSMB4, proteasome subunit beta type-4; TLN1, talin-1; TPM1, tropomyosin 1 chain;
UQCRC1, cytochrome b-c1 complex subunit 1; YWHAH, 14-3-3 protein eta.
Although platelets are enucleate cells, they do contain
stable pre-mRNA that is spliced into mature mRNA upon
platelet stimulation, leading to regulation of proteins. Thus,
platelets are able to respond to environmental change directly
by altering their protein composition [36]. Moreover, the dura-
tion of the intervention in this study would allow regulation
of gene expression in megakaryocytes. In this way, various
relevant pathways could be triggered such as, e.g., modulation
of prostaglandin synthesis [37–39]. Also, CLA may compete
with arachidonic acid and linoleic acid for cyclo-oxygenase
(COX1) once it is incorporated into platelet membranes [39].
CLA could also act as an agonist of peroxisome proliferator ac-
tivated receptors (PPARs) [40–42]. These nuclear receptors are
present on platelets and involved in agonist-induced platelet
function [43, 44].
Mapping of proteomics results is an elegant way to han-
dle a more extensive dataset in a partly objective manner.
Though care should be taken because the selection of the
database used for the mapping may not be complete or based
on the most recent evidence. This can be overcome by the
simultaneous use of several databases. Network visualiza-
tion of our proteomics dataset revealed that supplementation
with the 80:20 cis9,trans11 CLA blend regulated the central
protein hubs, GTP-binding protein CDC42hs, alpha-actinin-
1, and integrin alpha-IIb precursor. We found that the 80:20
cis9,trans11 CLA blend decreased protein levels of CDC42hs
in platelets. CDC42hs has been implicated as an important
mediator of filopodia formation, which plays an important
role in platelet adhesion [45], although a recent study found
that platelets from a murine knock out of CDC42hs were able
to form filopodia and spread fully on fibrinogen upon activa-
tion [46]. However, CDC42hs was also shown to play impor-
tant roles in the regulation of platelet activation, granule orga-
nization, degranulation, and GPIb signaling [46]. CDC42hs
belongs to the Rho GTPase family involved in changes
in cell morphology. These signaling proteins are tightly
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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regulated by both activation state and subcellular location
[47]. Activated Rho GTPase proteins are GTP bound and as-
sociated with their target membrane proteins [47, 48], which
could explain why we found lower levels of this protein on
the 2D gels. However, this seems unlikely because levels of
GDI-dissociation inhibitor protein 1, which is an inhibitory
regulator for Rho family GTPases through binding and ex-
tracting Rho family proteins from plasma and intracellular
membranes, were actually increased in platelets after supple-
mentation with the 80:20 cis9,trans11 CLA blend. Rho GDP-
dissociation inhibitor protein has, on the other hand, been
shown to inhibit thrombin-induced aggregation in vitro [49].
Supplementation with the 80:20 cis9,trans11 CLA blend also
affected proteins of the actin family. Actins are highly con-
served structural proteins and the most abundant proteins in
platelets. They are responsible for cell motility, e.g., the exten-
sion of F-actin filaments in the cytoskeleton to form filopodia
in activated platelets [45]. The exact mechanism by which
up-regulation of actin protein levels by the 80:20 cis9,trans11
CLA blend may affect platelet function is not known, but
may involve the promotion of cytoskeletal stability of the rest-
ing platelet, and reducing the incidence of shape change in
response to external stimuli.
The precursor for the alpha-IIb subunit of the platelet-
specific integrin IIb3, was another protein hub regulated
by the 80:20 cis9,trans11 CLA blend. In addition, CLA supple-
mentation was also associated with down-regulated protein
levels of fibrinogen  and  chains, and up-regulated protein
levels of coagulation factor XIII (FXIII) A chain (Table 2).
The IIb3 receptor contains the binding site for fibrinogen,
the major ligand for platelet aggregation [50]. Fibrinogen is
also the precursor of the fibrin clot, which is cross-linked and
stabilized by FXIII. Both fibrinogen and FXIII are key pro-
teins in the final step of the coagulation cascade in plasma
[51], but they are also present in platelets where their role is
much less understood. Previous human intervention studies
have revealed inconsistent effects on plasma fibrinogen levels
upon CLA supplementation, perhaps relating to differences
in the health status of the volunteers and the type of isomeric
mixture used [32, 33, 52].
The pathway, as mapped in KEGG, that contained a high
amount of regulated proteins in our dataset, was the fo-
cal adhesion pathway with seven altered proteins (Fig. 1).
Adhesion to an extracellular matrix is a critical step in the
platelet aggregation [53] and also a complex process involving
a diversity of proteins such as transmembrane receptors of
the integrin family, actins and filamins [54]. Filamin-A is a
280 kDa actin-binding protein, but it also binds GTPases
of the Ras superfamily as well as CDC42hs in a GTP-
independent way [55]. The binding of filamin to the GPIb-
IX-V complex is critical to form a link to von Willebrand
factor. When the filamin binding is disturbed, platelets are
less likely to aggregate by shear stress although they will
respond to thrombin or ADP [56]. In our study, the 80:20
cis9,trans11 CLA blend lowered protein levels of filamin-A.
In addition, we observed that CLA decreased levels of the cy-
toskeletal platelet protein talin-1. Talin consists of N-terminal
globular head of around 50 kDa and a C-terminal rod-like tail
of around 220 kDa. The N-terminal head contains a FERM
domain, which binds the cytosolic domains of integrin 
whereas the C-terminal tail provides a second integrin bind-
ing site and additional binding sites for F-actin and vinculin
[57, 58]. The FERM domain is essential for integrin activa-
tion and platelet aggregation [59] and needs to interact with
the 3 subunit of the integrin IIb3 so that the recruited
talin can activate IIb3 [60]. Talin-1 deficient fibroblast-like
cells showed delayed initiation and stabilization of focal com-
plexes slowing down focal adhesion [61]. Overexpression of
the FERM domain leads to integrin activation, e.g., IIb3
[62, 63], whereas talin knock-down in megakaryocytes and
mouse models impaired agonist-induced IIb3 activation
[64–66]. This indicates that the 80:20 cis9,trans11 CLA blend
may be able to modulate platelet adhesion through down-
regulation or shift of post-translationally modified isoforms
of talin-1 in platelets.
In conclusion, this comprehensive study of platelet pro-
teomics in a dietary trial of a 80:20 cis9,trans11 CLA blend
revealed many intriguing findings worthy of further inves-
tigation. The focal adhesion pathway appeared an important
mechanism of action which could contribute to the previously
reported antiatherogenic effects of dietary cis9,trans11 CLA.
Furthermore, the proteins CDC42hs, alpha-actinin-1 and in-
tegrin alpha-IIb precursor represent important protein hubs
that are regulated by the 80:20 cis9,trans11 CLA blend. These
proteins, or indeed downstream proteins or metabolites, are
likely candidate biomarkers that could be used in future nu-
tritional intervention studies to measure the efficacy of fatty
acids on platelet function.
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